Department of Pulmonary/Critical Care, Respiratory Institute, 2569Cleveland Clinic, OH, USA.
Department of Pathology, Pathology and Laboratory Medicine Institute, 2569Cleveland Clinic Foundation, OH, USA.
J Intensive Care Med. 2021 May;36(5):604-611. doi: 10.1177/0885066620981891. Epub 2020 Dec 30.
Patients with COVID-19 and ARDS on prolonged mechanical ventilation are at risk for developing endotracheal tube (ETT) obstruction that has not been previously described in patients with ARDS due to other causes. The purpose of this report is to describe a case series of patients with COVID-19 and ARDS in which ETT occlusion resulted in significant clinical consequences and to define the pathology of the obstructing material.
Incidents of ETT occlusion during mechanical ventilation of COVID-19 patients were reported by clinicians and retrospective chart review was conducted. Statistical analysis was performed comparing event rates between COVID-19 and non-COVID 19 patients on mechanical ventilation over the predefined period. Specimens were collected and submitted for pathological examination.
Eleven COVID-19 patients experienced endotracheal tube occlusion over a period of 2 months. Average age was 69 (14.3, range 33-85) years. Mean APACHE III score was 73.6 (17.3). All patients had AKI and cytokine storm. Nine exhibited biomarkers for hypercoagulability. Average days on mechanical ventilation before intervention for ETT occlusion was 14 (5.18) days (range of 9 to 23 days). Five patients were discharged from the ICU, and 4 expired. Average documented airway resistance on admission was 14.2 (3.0) cm HO/L/sec. Airway resistance before tube exchange was 28.1 (8.0) cm HO /L/sec. No similar events of endotracheal tube occlusion were identified in non-COVID patients on mechanical ventilation during the same time period. Microscopically, the material consisted of mucin admixed with necrotic cell debris, variable numbers of degenerated inflammatory cells, oral contaminants and red blood cells.
Patients with COVID-19 and ARDS on prolonged mechanical ventilation are at risk for developing ETT obstruction due to deposition of a thick, tenacious material within the tube that consists primarily of mucin and cellular debris. Clinicians should be aware of this dangerous but treatable complication.
COVID-19 患者并发急性呼吸窘迫综合征(ARDS)并接受长时间机械通气治疗,存在此前由其他原因导致 ARDS 患者中未描述过的气管内导管(ETT)阻塞风险。本报告旨在描述一组 COVID-19 并发 ARDS 患者,其 ETT 阻塞导致严重临床后果,并明确阻塞物质的病理学特征。
临床医生报告 COVID-19 患者机械通气期间 ETT 阻塞事件,回顾性病历审查。在预先设定的时间段内,比较 COVID-19 与非 COVID-19 机械通气患者的事件发生率,进行统计学分析。收集标本并提交进行病理学检查。
在 2 个月期间,11 例 COVID-19 患者经历了气管内导管阻塞。平均年龄 69(14.3,范围 33-85)岁。平均急性生理与慢性健康评分 III(APACHE III)为 73.6(17.3)。所有患者均有急性肾损伤和细胞因子风暴。9 例表现出高凝标志物。干预 ETT 阻塞前平均机械通气天数为 14(5.18)天(范围 9 至 23 天)。5 例患者从 ICU 出院,4 例死亡。入院时平均记录的气道阻力为 14.2(3.0)cmH2O/L/sec。更换气管导管前气道阻力为 28.1(8.0)cmH2O/L/sec。在同一时间段内,机械通气的非 COVID 患者未发生类似的气管内导管阻塞事件。显微镜下,该物质主要由黏蛋白和坏死细胞碎片、数量不等的退行性炎症细胞、口腔污染物和红细胞混合组成。
长时间机械通气的 COVID-19 并发 ARDS 患者存在 ETT 阻塞风险,原因是管内沉积了一种厚而坚韧的物质,主要由黏蛋白和细胞碎片组成。临床医生应意识到这种危险但可治疗的并发症。